Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A Phase IIa, multicenter, randomized, vehicle-controlled study.
You’ve clicked on a link for a third-party site, which Dermira, Inc., a wholly-owned subsidiary of Eli Lilly & Company, does not control, influence, or endorse. Dermira is not responsible for any content on this third-party site, including the privacy policy. Click “Continue” to leave or “Return” to return to Dermira.com.
